These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12639942)

  • 1. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.
    Florio T; Morini M; Villa V; Arena S; Corsaro A; Thellung S; Culler MD; Pfeffer U; Noonan DM; Schettini G; Albini A
    Endocrinology; 2003 Apr; 144(4):1574-84. PubMed ID: 12639942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways.
    Arena S; Pattarozzi A; Corsaro A; Schettini G; Florio T
    Mol Endocrinol; 2005 Jan; 19(1):255-67. PubMed ID: 15388796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation.
    Gonzalez C; Corbacho AM; Eiserich JP; Garcia C; Lopez-Barrera F; Morales-Tlalpan V; Barajas-Espinosa A; Diaz-Muñoz M; Rubio R; Lin SH; Martinez de la Escalera G; Clapp C
    Endocrinology; 2004 Dec; 145(12):5714-22. PubMed ID: 15358675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase.
    Eto M; Barandiér C; Rathgeb L; Kozai T; Joch H; Yang Z; Lüscher TF
    Circ Res; 2001 Sep; 89(7):583-90. PubMed ID: 11577023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis.
    Lovren F; Pan Y; Shukla PC; Quan A; Teoh H; Szmitko PE; Peterson MD; Gupta M; Al-Omran M; Verma S
    Am J Physiol Endocrinol Metab; 2009 Jun; 296(6):E1440-9. PubMed ID: 19351806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells.
    Andreozzi F; Laratta E; Sciacqua A; Perticone F; Sesti G
    Circ Res; 2004 May; 94(9):1211-8. PubMed ID: 15044323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis.
    Mehta VB; Zhou Y; Radulescu A; Besner GE
    Growth Factors; 2008 Dec; 26(6):301-15. PubMed ID: 18925469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous production of nitric oxide by vascular endothelial growth factor down-regulates proliferation of choriocarcinoma cells.
    Cha MS; Lee MJ; Je GH; Kwak JY
    Biochem Biophys Res Commun; 2001 Apr; 282(4):1061-6. PubMed ID: 11352660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
    Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the mitogen-activated protein kinase cascade is necessary but not sufficient for basic fibroblast growth factor- and epidermal growth factor-stimulated expression of endothelial nitric oxide synthase in ovine fetoplacental artery endothelial cells.
    Zheng J; Bird IM; Melsaether AN; Magness RR
    Endocrinology; 1999 Mar; 140(3):1399-407. PubMed ID: 10067868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of shear stress-induced endothelial nitric-oxide synthase phosphorylation and expression in ovine fetoplacental artery endothelial cells.
    Li Y; Zheng J; Bird IM; Magness RR
    Biol Reprod; 2004 Mar; 70(3):785-96. PubMed ID: 14627548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis.
    Moraes MS; Costa PE; Batista WL; Paschoalin T; Curcio MF; Borges RE; Taha MO; Fonseca FV; Stern A; Monteiro HP
    Arch Biochem Biophys; 2014 Sep; 558():14-27. PubMed ID: 24960080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte growth factor activates endothelial nitric oxide synthase by Ca(2+)- and phosphoinositide 3-kinase/Akt-dependent phosphorylation in aortic endothelial cells.
    Makondo K; Kimura K; Kitamura N; Kitamura T; Yamaji D; Jung BD; Saito M
    Biochem J; 2003 Aug; 374(Pt 1):63-9. PubMed ID: 12757411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
    Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
    Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo.
    Uchiba M; Okajima K; Oike Y; Ito Y; Fukudome K; Isobe H; Suda T
    Circ Res; 2004 Jul; 95(1):34-41. PubMed ID: 15166095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.